within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M01C_SpecificAntirheumaticAgents.M01CB04_Aurothioglucose;

model Aurothioglucose
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 1.9444444444444445e-07,
    adminDuration = 600,
    adminMass = 50 / 1000000,
    adminCount = 1,
    Vd = 0.00023,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Aurothioglucose</td></tr><tr><td>ATC code:</td><td>M01CB04</td></tr><td>route:</td><td>intramuscular</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>50</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.23</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.01</td><td>L/kg/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Aurothioglucose is a gold-containing compound formerly used as a disease-modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis. It is administered via intramuscular injection and acts by modulating immune responses, but its use has greatly diminished due to safety concerns and the advent of more effective agents. It is not commonly used in current clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are not well characterized in recent literature. Existing reports suggest a one-compartment model after intramuscular administration in adults with rheumatoid arthritis.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.M.M01CB04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Aurothioglucose;
